<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191526</url>
  </required_header>
  <id_info>
    <org_study_id>0761HAM-001</org_study_id>
    <nct_id>NCT03191526</nct_id>
  </id_info>
  <brief_title>A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of KW-0761 after intravenous
      injections in subjects with HTLV-1 associated myelopathy (HAM) in Japan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of KW-0761 (0.3 mg/kg) on the Osame's motor disability score (OMDS) of subjects
      with HTLV-1 associated myelopathy (HAM).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Osame's motor disability score</measure>
    <time_frame>At week 4, 8 and 12 after second injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HTLV-1 Proviral load in peripheral blood</measure>
    <time_frame>Pre-dose, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of twice 10 m walking time</measure>
    <time_frame>Pre-dose, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Scale</measure>
    <time_frame>Pre-dose, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Clinical Global Impression (CGI-I)</measure>
    <time_frame>Pre-dose, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Clinical Global Impression (VAS)</measure>
    <time_frame>Pre-dose, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Urinary dysfunction (OABSS)</measure>
    <time_frame>Pre-dose, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Urinary dysfunction (I-PSS)</measure>
    <time_frame>Pre-dose, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sensory dysfunction (numbness in the lower limbs (VAS))</measure>
    <time_frame>Pre-dose, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sensory dysfunction (Pain in the lower limbs (VAS))</measure>
    <time_frame>Pre-dose, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neopterine Concentration in CSF</measure>
    <time_frame>At week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>HTLV-1 Associated Myelopathy</condition>
  <arm_group>
    <arm_group_label>KW-0761 0.3 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-0761 0.3 mg/kg IV</intervention_name>
    <description>Intravenous injection every 12 weeks.</description>
    <arm_group_label>KW-0761 0.3 mg/kg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <description>Intravenous injection every 12 weeks.</description>
    <arm_group_label>Placebo (saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntary written informed consent to participate in the study

          2. Diagnosis as HAM according to the second edition of HAM Treatment Manual

          3. At least 1-year history of HAM

          4. Ongoing medication*1 for HAM, with no changes in 3 months before enrollment; or
             inadequate response or intolerance to prior medication,*2 which must have been
             discontinued for at least 3 months before enrollment. Subjects on maintenance therapy
             with steroids must have been receiving ≤ 10 mg/day prednisolone equivalent
             continuously for at least 3 months before enrollment.

               -  1 Steroids, salazosulfapyridine, or ≥ 1.5 g/day vitamin C

               -  2 Steroids, Interferon-α, salazosulfapyridine, or ≥ 1.5 g/day vitamin C

          5. No change in the degree of motor dysfunction for at least 3 months before the date of
             screening, as judged by the investigator or subinvestigator

          6. A OMDS of ≥3 at screening and able to walk ≥10 m at screening (use of a single cane or
             double canes is allowed)

        Exclusion Criteria:

          1. Any of the following significant concomitant diseases:

             Type 1 diabetes mellitus, Poorly controlled type 2 diabetes mellitus (HbA1c (NGSP) &gt;
             8.5%), Congestive heart failure (Class II to IV of the New York Heart Association
             Functional Classification), Myocardial infarction within 1 year before enrollment,
             Unstable angina within 1 year before enrollment, Poorly controlled hypertension
             (systolic blood pressure &gt; 150 mm Hg and diastolic blood pressure &gt; 90 mm Hg at
             screening), Sever chronic lung disease requiring oxygen therapy, Multiple sclerosis or
             any other demyelinating disease, Epilepsy requiring treatment with antiepileptics
             (with the exception of epilepsy controlled by antiepileptics, with no occurrence of
             seizures for at least 3 years before informed consent), and Active malignancy
             (including ATL); or onset of malignancy or previous treatment for malignancy (with the
             exception of resected or surgically cured intraepithelial carcinoma of the uterine
             cervix, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or
             ductal breast carcinoma) within 5 years before informed consent

          2. Active infection

          3. Concurrent spinal cord compression lesion (e.g., cervical spine diseases, disk
             herniation, or ossification of the ligamentum flavum) , with the exception of
             conditions that would not affect efficacy evaluation in the study, as judged by the
             investigator or subinvestigator

          4. Concurrent dementia

          5. Concurrent psychiatric disorder, with the exception of conditions that would not
             affect obtaining informed consent or efficacy evaluation in the study, as judged by
             the investigator or subinvestigator

          6. History of or current alcohol or drug dependence

          7. Planned surgery during the study period

          8. Any other conditions unsuitable for participation in the study in the opinion of the
             investigator or subinvestigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nagoya University Hosipital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital</name>
      <address>
        <city>Tone</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <state>Fukuoka Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <state>Fukuoka Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Occupational and Environmental Health, Japan</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima City Hospital</name>
      <address>
        <city>Kagoshima</city>
        <state>Kagoshima Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima</city>
        <state>Kagoshima Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <state>Kumamoto Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hosipital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujimoto General Hospital</name>
      <address>
        <city>Miyakonojō</city>
        <state>Miyazaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oita Prefectural Hospital</name>
      <address>
        <city>Oita</city>
        <state>Oita Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Okinawa National Hospital</name>
      <address>
        <city>Ginowan</city>
        <state>Okinawa Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Ryukyus Hospital</name>
      <address>
        <city>Nakagami</city>
        <state>Okinawa Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hosipital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hosipital, Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Paraparesis, Tropical Spastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

